Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
83%
Hematopoietic Cell Transplantation
37%
Confidence Interval
28%
Overall Survival
25%
Multiple Myeloma
23%
Pretransplant
19%
Acute Myeloid Leukemia
18%
Clinical Outcomes
17%
Unrelated Donor
16%
Microbiome
15%
Disease States
14%
Pancreatic Cancer
14%
Mycobiome
14%
Post-transplantation Cyclophosphamide (PTCy)
14%
Steroid-sensitive
12%
Lymphoma
12%
Frailty
11%
Health Status
11%
Hematological Malignancies
11%
Steroid Use
10%
Reduced-intensity Conditioning
10%
Umbilical Cord Blood Transplantation
10%
Hematopoietic Stem Cell Transplantation
10%
Human Host
10%
Hematopoietic Cells
9%
Myeloablative
9%
Health Impact
9%
Collaborative Study
9%
Life-threatening
9%
Human Chorionic Gonadotropin
9%
Epidermal Growth Factor
9%
Accelerated Aging
9%
Keratinocyte Growth Factor
9%
Donor Lymphocyte Infusion
8%
Progression-free Survival
8%
Steroid Resistance
8%
Mycophenolate Mofetil
8%
Non-relapse Mortality
8%
Cumulative Incidence
8%
Cancer Survivors
7%
High Risk
7%
Tacrolimus
7%
Treatment Toxicity
7%
Acute Lymphoblastic Leukemia
7%
Risk Factors
7%
Umbilical Cord Blood
7%
Chimeric Antigen Receptor T Cells (CAR-T)
7%
Treatment Response
6%
University of Minnesota
6%
Immunology and Microbiology
Hematopoietic Cell
78%
Cell Transplantation
77%
Graft-Versus-Host Disease
52%
Chronic Graft Versus Host Disease
48%
Acute Graft Versus Host Disease
33%
Transplant Procedure
26%
Overall Survival
25%
Microbiome
22%
Umbilical Cord Blood
20%
Cyclophosphamide
14%
Mycobiome
14%
Mycophenolic Acid
12%
Cord Blood Stem Cell Transplantation
12%
Engraftment
10%
Drug Megadose
10%
Allotransplantation
9%
Epidermal Growth Factor
9%
Tacrolimus
9%
Platelet
8%
Multiple Myeloma
7%
Conditioning
6%
Microorganism
6%
Failure Free Survival
6%
Hematopoietic Stem Cell Transplantation
6%
Progression Free Survival
5%
Immunosuppression
5%
Metabolite
5%
Microflora
5%
Myeloid
5%
Metagenome
5%
CD34
5%
Intestine Flora
5%
Prevalence
5%
Bone Marrow Transplantation
5%
Medicine and Dentistry
Hematopoietic Stem Cell
49%
Cell Transplantation
44%
Chronic Graft Versus Host Disease
36%
Graft Versus Host Reaction
31%
Overall Survival
20%
Frailty
19%
Transplantation
17%
Multiple Myeloma
17%
Acute Graft Versus Host Disease
16%
Acute Myeloid Leukemia
15%
Pancreas Cancer
14%
Malignant Neoplasm
14%
Disease
12%
Cord Blood
10%
Hematopoietic Stem Cell Transplantation
9%
Chorionic Gonadotropin
9%
Epidermal Growth Factor
9%
Urinary System
8%
Cancer Therapy
8%
Platelet
7%
Acute Lymphoblastic Leukemia
7%
Clinical Trial
7%
Failure Free Survival
6%
Quality of Life
6%
Prevalence
6%
Hematologic Malignancy
6%
Treatment Response
6%
Accelerated Aging
6%
Chimeric Antigen Receptor T-Cell
5%
Progression Free Survival
5%
Disease Severity
5%
Patient-Reported Outcome
5%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%
Neoplasm
5%
Endothelial Dysfunction
5%
Cumulative Incidence
5%